Focus: Tanabe Pharma America is a specialty pharmaceutical company focused on neurology and rare disease with a marketed portfolio anchored by RADICAVA (edaravone). The company operates as the US subsidiary of a larger parent entity.
Profile data last refreshed 4h ago · AI intelligence enriched 2w ago
Cooling — net -6 jobs in 30d
0 added, 6 removed. Slower than typical.
Tanabe Pharma America offers niche therapeutic expertise and pipeline upside in rare diseases, but extreme revenue concentration and limited hiring indicate a transitional company with higher-than-typical execution risk.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Sole revenue driver representing 100% of company revenue; available in IV and oral formulations with expanding indications beyond ALS.
Help build intelligence for Tanabe Pharma America
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Tanabe Pharma America's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles